Pretreatment platelet count predicts survival outcome of patients with de novo non-M3 acute myeloid leukemia.

ABSTRACT:

Background

Pretreatment platelet count has been reported as a potential tool to predict survival outcome in several solid tumors. However, the predictive value of pretreatment platelet count remains obscure in de novo acute myeloid leukemia (AML) excluding acute promyelocytic leukemia (M3).

Methods

We conducted a retrospective review of 209 patients with de novo non-M3 AML in our institute over a period of 8 years (2007-2015). Receiver operating characteristic (ROC) curve analysis was used to determine the optimal platelet (PLT) cutoff in patients. We analyzed the overall survival (OS) and disease free survival (DFS) using the log-rank test and Cox regression analysis.

Results

By defining the platelet count 50 × 10⁹/L and 120 × 10⁹/

SUBMITTER: Zhang Q 

PROVIDER: S-EPMC5742276 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature